Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset.

Umang Swami,Jennifer Anne Sinnott,Ben Haaland,Benjamin Louis Maughan,Nityam Rathi,Taylor Ryan McFarland,Manish Kohli,Roberto H. Nussenzveig,Sumanta K. Pal,Neeraj Agarwal

Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset.

2020

Umang Swami
Jennifer Anne Sinnott
Ben Haaland
Benjamin Louis Maughan
Nityam Rathi
Taylor Ryan McFarland
Manish Kohli
Roberto H. Nussenzveig
Sumanta K. Pal
Neeraj Agarwal

5537Background: NHT (A and E) are approved first-line (1L) treatment (Rx) for mPC. After progression on NHT, Rx include either alternate NHT or D. However, OS from a randomized trial comparing NHT ...

Keywords:

Oncology
Hormonal therapy
Enzalutamide
Abiraterone
overall survival
in patient
Internal medicine
Prostate cancer
Pathology
Medicine
Docetaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations